Source: Empower Clinics Inc.
  • Empower Clinics (CBDT) has announced that it will close two The Medi-Collective (TMC) clinics in Hamilton and Mississauga
  • Both clinics will no longer operate under TMC as of September 1, 2022
  • Six Ontario clinics will continue to operate
  • Empower is a wellness healthcare company that provides patients clinics with digital, telemedicine care, and medical diagnostics laboratories
  • Empower Clinics Inc. (CBDT) opened trading at C$0.05

Empower Clinics (CBDT) has announced that it will close two The Medi-Collective (TMC) clinics in Hamilton and Mississauga.

Both clinics will no longer operate under TMC as of September 1, 2022.

“After analyzing the operations of our TMC clinics and taking into consideration the potential for future growth, we’ve decided that both Hamilton and Mississauga clinics do not fully meet our expansion goals”, stated Steven McAuley, Chairman and CEO of Empower Clinics.

“These decisions are not made lightly but we need to adjust to our current climate and invest our resources where patients can experience truly integrated health care.”

Carolyn Shields, Senior Vice President of Operations for TMC, added,

“These two locations are the smallest of our clinics and don’t have the optimal ability to add wellness or private services. In the current healthcare landscape with a severe shortage of physicians, TMC needs to focus on clinics that maximize revenue opportunities by offering integrated health care with both traditional medical and wellness solutions.”

Empower is a wellness healthcare company that provides patients clinics with digital, telemedicine care and medical diagnostics laboratories.

Empower Clinics Inc. (CBDT) opened trading at C$0.05.


More From The Market Online

Calian scores $23 million Canadian Armed Forces contract

Calian Group Ltd. (TSX:CGY) has been awarded a $17 million contract by the Canadian Armed Forces’ Canadian Forces Health Services Group.

Unsung profits: Three microcap stocks with a strong case for value

A key factor behind picking winning microcap value stocks is identifying dislocations between company performance and market perception.

This life sciences company is gearing up to treat long COVID  

Revive Therapeutics (CSE:RVV), a Toronto-based company, has immense potential to capitalize on treating long COVID symptoms.

Theralase advances cancer research after private placement

Theralase Technologies (TSXV:TLT) closes a non-brokered private placement offering of 4.1 million shares for gross proceeds of C$750,200.